CRC 220

Drug Profile

CRC 220

Latest Information Update: 03 Jul 2002

Price : $50

At a glance

  • Originator Aventis Behring LLC
  • Class Antithrombotics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Disseminated intravascular coagulation; Thrombosis

Most Recent Events

  • 24 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis
  • 15 Oct 1998 A preclinical study has been added to the Thromboses pharmacodynamics section
  • 15 Oct 1998 An animal study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top